ESMO Symposium on Signalling Pathways in Cancer 2014

Oncology Meeting Resources

28 Feb - 01 Mar, Sitges, Spain

Signalling Pathways 2014

Please find below the links to all Signalling Pathways in Cancer 2014 presentations that have a slide set or webcast. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Search Meeting Resources by Keyword

Useful links

Presenter Presentation title Session title
Cristiana Sessa Introduction and welcome Introduction and Welcome
Massimo Broggini Introduction to the PI3K pathway The basis of signal transduction
George Thomas Introduction to the mTOR pathway and protein transduction The basis of signal transduction
Andrea Alimonti PTEN Pre-clinical data, I
Bryan Hennessy Biomarkers in the pre-clinical setting Pre-clinical data, II
Jordi Rodon Distinctive features of the main classes: mTOR, PI3K, dual inhibitors & AKT Clinical development of PI3K/AKT/mTOR inhibitors
Johann de Bono Predictive biomarkers and pharmacodynamics of PI3K/AKT/mTOR inhibitors Clinical development of PI3K/AKT/mTOR inhibitors
Philippe Bedard Toxicity and metabolic aspects Clinical development of PI3K/AKT/mTOR inhibitors
Cristian Massacesi Drawbacks and improvements Clinical development of PI3K/AKT/mTOR inhibitors
Monica Arnedos Toxicity of mTOR inhibitors and PI3K Management of toxicity
Cristiana Sessa Toxicity of combinations Management of toxicity
Thomas Bachelot Efficacy of mTOR inhibition Breast cancer
Cristina Saura Clinical development of PI3K Breast cancer
Fabrice André Rationale for combination strategies Breast cancer
Sibylle Loibl Combinations with chemotherapy Breast cancer